Ivarmacitinib Study for Moderate-to-Severe Atopic Dermatitis
ClinicalTrials.gov Studies
Summary
This prospective, multicenter, real-world study evaluated the efficacy and safety of switching to ivarmacitinib, a JAK1 inhibitor, in patients with moderate-to-severe atopic dermatitis who had inadequate response to IL-4Rα inhibitors. The study followed participants over 16 weeks under real-world conditions and found no additional burden for participants. Ivarmacitinib sulfate tablets were the sole intervention studied.
“This study assessed the efficacy and safety of switching to the JAK1 inhibitor ivarmacitinib over 16 weeks in patients with moderate-to-severe atopic dermatitis and inadequate response to IL-4Rα inhibitors under real-world conditions.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The ClinicalTrials.gov registry entry documents NCT07550452, a prospective, multicenter, real-world study evaluating ivarmacitinib in patients with moderate-to-severe atopic dermatitis who did not respond adequately to IL-4Rα inhibitors. The study assessed efficacy and safety of switching to ivarmacitinib sulfate tablets over a 16-week period under routine clinical practice conditions.
For pharmaceutical companies and clinical investigators, this registry entry indicates ongoing real-world evidence generation for JAK1 inhibitors in atopic dermatitis following biologic failure. Sponsors developing similar dermatology programs may find this study design relevant for comparative effectiveness research planning.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study
N/A NCT07550452 Kind: NA Apr 24, 2026
Abstract
Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.
This study assessed the efficacy and safety of switching to the JAK1 inhibitor ivarmacitinib over 16 weeks in patients with moderate-to-severe atopic dermatitis and inadequate response to IL-4Rα inhibitors under real-world conditions.
It is expected that there will be no additional burden for participants in this trial.
Conditions: Atopic Dermatitis (AD)
Interventions: Ivarmacitinib Sulfate Tablets
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.